Delayed trial readouts
Studies whose primary completion date moved on ClinicalTrials.gov in the last 180 days, newest first. The primary completion date is the sponsor's own estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout. Our daily registry check records each move the day it sees it. Upcoming dates are on the readout calendar.
Summary
2,453 date moves: 1,669 later and 784 earlier. The median move later is 246 days.
Date moves
| Seen | Drug | Study | Phase | Old date | New date | Move |
|---|---|---|---|---|---|---|
| 2026-11-20 | aldesleukin | NCT01704716High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) | Phase 3 | 2021-09-30 | 2025-01-30 | +1218 days |
| 2026-11-20 | Gemcitabine, Sintilimab | NCT05979818Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer | Phase 1/2 | 2025-08-31 | 2028-10-31 | +1157 days |
| 2026-11-20 | Capecitabine, Gemcitabine, Eribulin mesylate | NCT06143553Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer | Phase 3 | 2025-12 | 2027-12-31 | +760 days |
| 2026-11-20 | Dexamethasone, Ofatumumab, Rituximab, Blinatumomab, Methotrexate | NCT02877303Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | Phase 2 | 2026-11-01 | 2028-11-01 | +731 days |
| 2026-11-20 | Methotrexate | NCT06252870Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation | Phase 2 | 2027-10-18 | 2029-10-18 | +731 days |
| 2026-11-20 | Bortezomib, Abatacept | NCT05289167Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) | Phase 1/2 | 2026-08 | 2027-11 | +457 days |
| 2026-11-20 | Disitamab Vedotin | NCT06660511Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination With Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. | Phase 1 | 2025-09-01 | 2026-12-01 | +456 days |
| 2026-11-20 | Semaglutide (Ozempic) | NCT06387199Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide | Phase 2/3 | 2027-01 | 2027-12 | +334 days |
| 2026-11-20 | Atezolizumab | NCT05498896Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC | Phase 2 | 2026-08-31 | 2027-05-31 | +273 days |
| 2026-11-20 | Elacestrant, Abemaciclib | NCT05386108Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | Phase 1/2 | 2026-12 | 2027-08 | +243 days |
| 2026-11-20 | Letrozole | NCT04111978MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | Phase 3 | 2027-07-01 | 2028-02-01 | +215 days |
| 2026-11-20 | Blinatumomab | NCT03595917ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML | Phase 1 | 2026-11-01 | 2027-06-01 | +212 days |
| 2026-11-20 | Capivasertib, Osimertinib | NCT07486648Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib | Phase 1/2 | 2028-10-15 | 2029-05-15 | +212 days |
| 2026-11-20 | Sapanisertib | NCT06385496Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) | Phase 2 | 2026-12-31 | 2027-06-30 | +181 days |
| 2026-11-20 | Sapanisertib | NCT06390865Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) | Phase 2 | 2026-12-31 | 2027-06-30 | +181 days |
| 2026-11-20 | Axitinib intravitreal implant (OTX-TKI) | NCT05695417Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy | Phase 1 | 2024-01 | 2024-05-28 | +148 days |
| 2026-11-20 | ontunisertib | NCT07672574Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers | Phase 1 | 2026-09-26 | 2027-01-31 | +127 days |
| 2026-11-20 | Rifaximin SSD | NCT05071716Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | Phase 3 | 2025-09 | 2025-12-23 | +113 days |
| 2026-11-20 | Zoledronic acid | NCT03295981Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone | Phase 3 | 2027-01 | 2027-04 | +90 days |
| 2026-11-20 | Oxycodone (Xtampza ER) | NCT03823534Post-Op Pain Control for Prophylactic Intramedullary Nailing. | Phase 3 | 2026-12-31 | 2027-03-31 | +90 days |
| 2026-11-20 | Goserelin | NCT07777263ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV) | Phase 3 | 2035-10 | 2035-12 | +61 days |
| 2026-11-20 | SHR-1139 | NCT07078695A Trial of SHR-1139 in Healthy Volunteers | Phase 1 | 2026-09-30 | 2026-11-09 | +40 days |
| 2026-11-20 | Semaglutide (Wegovy) | NCT07845994SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years | Phase 3 | 2031-02 | 2031-03 | +28 days |
| 2026-11-19 | Anakinra | NCT05805930Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in Children | Phase 3 | 2025-06-01 | 2027-10-01 | +852 days |
| 2026-11-19 | Silevertinib | NCT05256290Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations | Phase 1/2 | 2025-11-03 | 2028-03 | +849 days |
| 2026-11-19 | Trastuzumab Deruxtecan, Afatinib | NCT06085755Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer | Phase 1/2 | 2025-12 | 2027-12-01 | +730 days |
| 2026-11-19 | Colesevelam | NCT06197763Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation. | Phase 1/2 | 2025-11-01 | 2027-07-30 | +636 days |
| 2026-11-19 | Fulvestrant | NCT05826964Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer | Phase 2 | 2026-07-31 | 2027-11-30 | +487 days |
| 2026-11-19 | Niraparib, Bevacizumab | NCT04734665Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor | Phase 2 | 2023-03-31 | 2024-07-11 | +468 days |
| 2026-11-19 | Almonertinib | NCT06463171Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer | Phase 2 | 2026-06 | 2027-08-01 | +426 days |
| 2026-11-19 | Dexamethasone, Docetaxel | NCT04947189Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer | Phase 1/2 | 2026-07 | 2027-07-01 | +365 days |
| 2026-11-19 | Azacitidine, Venetoclax | NCT07163793Pilot Study of Reduced Venetoclax Exposure | Phase 2 | 2026-10 | 2027-10 | +365 days |
| 2026-11-19 | Ruxolitinib (Jakafi), Abatacept | NCT07238712Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor | Phase 2 | 2026-12-10 | 2027-12-10 | +365 days |
| 2026-11-19 | Tislelizumab | NCT07389187Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | 2026-12 | 2027-12 | +365 days |
| 2026-11-19 | Selpercatinib | NCT05668962Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | Phase 2 | 2025-03-01 | 2026-01-13 | +318 days |
| 2026-11-19 | teduglutide (Gattex) | NCT07400783TED_ORG: Study on Short Bowel Syndrome | Phase na | 2026-03 | 2027-01 | +306 days |
| 2026-11-19 | Tamoxifen (Soltamox) | NCT05156892Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer | Phase 1 | 2026-01-01 | 2026-11-01 | +304 days |
| 2026-11-19 | Sacituzumab Govitecan | NCT04559230Sacituzumab Govitecan in Recurrent Glioblastoma | Phase 2 | 2027-02 | 2027-08 | +181 days |
| 2026-11-19 | Povetacicept | NCT07204275Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) | Phase 2/3 | 2028-12-29 | 2029-06-27 | +180 days |
| 2026-11-19 | Psilocybin (COMP360) | NCT07373535Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy | Phase 2 | 2028-07 | 2028-12 | +153 days |
| 2026-11-19 | Ticagrelor | NCT06691191Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors | Phase 4 | 2026-08-31 | 2026-12-31 | +122 days |
| 2026-11-19 | AND017 | NCT07494409A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia | Phase 3 | 2026-10-30 | 2027-02-20 | +113 days |
| 2026-11-19 | AND017 | NCT07487727A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) | Phase 3 | 2026-12-01 | 2027-03-01 | +90 days |
| 2026-11-19 | tocilizumab | NCT05207670A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies | Phase 2 | 2027-07-31 | 2027-10-01 | +62 days |
| 2026-11-19 | efsubaglutide alfa | NCT07114419The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE) | Phase 2 | 2026-06-01 | 2026-07-06 | +35 days |
| 2026-11-19 | Dexamethasone, Cevostamab, Elotuzumab, Pomalidomide, Daratumumab, Carfilzomib | NCT07555938Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | Phase 3 | 2028-10-31 | 2028-11-30 | +30 days |
| 2026-11-19 | Depemokimab, Mepolizumab | NCT05263934Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | 2026-09-29 | 2026-10-06 | +7 days |
| 2026-11-18 | Sintilimab, Bevacizumab | NCT05363722Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCC | Phase 1 | 2023-04 | 2029-01 | +2102 days |
| 2026-11-18 | Patritumab Deruxtecan | NCT06172478A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Phase 2 | 2027-09-01 | 2030-11-19 | +1175 days |
| 2026-11-18 | Mitapivat | NCT05935202Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies | Phase 2 | 2025-07-15 | 2028-09-30 | +1173 days |
| 2026-11-18 | Obudanersen | NCT05127226HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome | Phase 1/2 | 2029-03 | 2032-03 | +1096 days |
| 2026-11-18 | Tobevibart (VIR-3434) | NCT07142811A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | Phase 2 | 2026-11 | 2029-03 | +851 days |
| 2026-11-18 | Futibatinib (Lytgobi), Amivantamab, Atezolizumab | NCT03767075A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) | Phase 2 | 2025-05 | 2027-05 | +730 days |
| 2026-11-18 | Ivabradine | NCT04111133Ivabradine in Cirrhotic Cardiomyopathy | Phase na | 2024-10 | 2026-10-01 | +730 days |
| 2026-11-18 | Gemcitabine, S-1, Tislelizumab | NCT06903273Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma | Phase 2 | 2028-07-01 | 2030-07-01 | +730 days |
| 2026-11-18 | tenofovir alafenamide (Vemlidy), lamivudine (Epivir-HBV), Tenofovir disoproxil fumarate (Viread), Doravirine, Bictegravir | NCT07075146DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity | Phase 3 | 2026-06-05 | 2027-12-05 | +548 days |
| 2026-11-18 | Letrozole | NCT06913075FET in Adenomyosis | Phase na | 2026-07-15 | 2027-09-15 | +427 days |
| 2026-11-18 | Dexamethasone, Ixazomib | NCT03618537Ixazomib Maintenance Study in Patients With AL Amyloidosis | Phase 2 | 2026-08 | 2027-08 | +365 days |
| 2026-11-18 | Binimetinib | NCT06159478Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer | Phase 2 | 2027-02-28 | 2028-02-28 | +365 days |
| 2026-11-18 | Rifaximin (Xifaxan) | NCT06538077BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE | Phase 4 | 2026-08 | 2027-08 | +365 days |
| 2026-11-18 | Cannabidiol (Epidiolex) | NCT06014424Cannabidiol Medication Intervention Trial | Phase 2 | 2026-12-29 | 2027-12 | +337 days |
| 2026-11-18 | IAM1363 | NCT06253871A Phase 1/2 Study of IAM1363 in HER2 Cancers | Phase 1/2 | 2027-12 | 2028-10 | +305 days |
| 2026-11-18 | Diroximel fumarate | NCT06913920Mechanical Modalities Combined With Standard Therapy Versus Standard Therapy Alone for Edema and Pain Management After Distal Radius Fracture Fixation | Phase na | 2026-01-15 | 2026-10-28 | +286 days |
| 2026-11-18 | Methotrexate, etanercept | NCT03728478STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS | Phase 3 | 2025-02-28 | 2025-10-31 | +245 days |
| 2026-11-18 | Diroximel fumarate | NCT06913894Supervised vs. Home-Based vs. No Therapy for Uncomplicated Distal Radius Fracture in Younger Adults | Phase na | 2026-04-21 | 2026-10-27 | +189 days |
| 2026-11-18 | faricimab | NCT06790784Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR | Phase 3 | 2031-08 | 2032-02 | +184 days |
| 2026-11-18 | Insulin Lispro | NCT06945406A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes | Phase 1 | 2027-03 | 2027-07 | +122 days |
| 2026-11-18 | viloxazine | NCT02736656Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | Phase 3 | 2026-09 | 2026-12 | +91 days |
| 2026-11-18 | Ranibizumab, Surabgene lomparvovec | NCT04514653RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2 | 2026-08 | 2026-10-13 | +73 days |
| 2026-11-18 | Temozolomide | NCT07935889Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 Trial | Phase 3 | 2035-11-02 | 2035-11-30 | +28 days |
| 2026-11-18 | Rabeprazole | NCT07797478A Study of RO7890597 in Healthy Adult Volunteers | Phase 1 | 2027-06-08 | 2027-06-15 | +7 days |
| 2026-11-17 | Duloxetine, Pregabalin, Gabapentin | NCT07593313Treatment of Post-Stroke Central Pain | Phase na | 2026-08-01 | 2029-08-01 | +1096 days |
| 2026-11-17 | Avelumab | NCT03774901Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma | Phase 2 | 2024-09-22 | 2026-10-30 | +768 days |
| 2026-11-17 | zanubrutinib, Rituximab | NCT05914662Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM | Phase 2 | 2025-03-15 | 2026-11-15 | +610 days |
| 2026-11-17 | zasocitinib | NCT07250802A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis | Phase 3 | 2033-01-24 | 2034-07-03 | +525 days |
| 2026-11-17 | Bevacizumab, Nab-paclitaxel, Relacorilant (Lifyorli) | NCT06906341Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | Phase 2 | 2026-08 | 2027-12 | +487 days |
| 2026-11-17 | TSN1611 | NCT06385925A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation | Phase 1/2 | 2026-10-30 | 2027-10-30 | +365 days |
| 2026-11-17 | Pembrolizumab | NCT03829254A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | Phase 1/2 | 2026-08 | 2027-07 | +334 days |
| 2026-11-17 | Empagliflozin | NCT07472920Empagliflozin Adjunctive Therapy in Bipolar Depression | Phase na | 2026-09 | 2027-08 | +334 days |
| 2026-11-17 | dupilumab | NCT05268107Ethnic Differences in Mechanisms of Action of Dupilumab | Phase 4 | 2026-12 | 2027-07 | +212 days |
| 2026-11-17 | Rituximab | NCT05600686Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | Phase 2 | 2026-10-01 | 2027-05-01 | +212 days |
| 2026-11-17 | Corteria COR-1167 | NCT06815471CRF2 Agonist for the Treatment of Worsening Heart Failure | Phase 2 | 2026-12 | 2027-07 | +212 days |
| 2026-11-17 | Nab-paclitaxel, Gemcitabine | NCT05064618Investigator-initiated Clinical Trial of MIKE-1 | Phase 1/2 | 2025-04-30 | 2025-10-02 | +155 days |
| 2026-11-17 | Axatilimab, Pembrolizumab | NCT07015853ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation | Phase 2 | 2033-07 | 2033-12 | +153 days |
| 2026-11-17 | Durvalumab | NCT03768570Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer | Phase 2 | 2026-10-31 | 2027-03-31 | +151 days |
| 2026-11-17 | Iparomlimab and tuvonralimab | NCT07613567QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer | Phase 3 | 2032-08-31 | 2032-12-31 | +122 days |
| 2026-11-17 | HRG2010 | NCT06596876A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations | Phase 3 | 2025-10-09 | 2026-01-29 | +112 days |
| 2026-11-17 | Pembrolizumab | NCT07732634Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer | Phase 2 | 2029-08 | 2029-11 | +92 days |
| 2026-11-17 | Dostarlimab | NCT07740720A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer | Phase 3 | 2029-12-12 | 2030-03-13 | +91 days |
| 2026-11-17 | Purinostat Mesylate | NCT07809217Mass Balance Study of [¹⁴C]Purinostat Mesylate for Injection in Healthy Participants | Phase 1 | 2026-10-31 | 2026-12-15 | +45 days |
| 2026-11-17 | VT-5006 | NCT07310264Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease | Phase 1 | 2026-09-28 | 2026-11-10 | +43 days |
| 2026-11-14 | Ceralasertib, Durvalumab | NCT03780608A Study of AZD6738 in Combination With Durvalumab in Patients With Refractory Solid Tumors (Cohort A: Chemotherapy-Refractory Gastric Cancer; Cohort B: Anti-PD(L) | Phase 2 | 2022-12-01 | 2027-12-01 | +1826 days |
| 2026-11-14 | BI 3000202 | NCT06878365A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies | Phase 1 | 2026-12-06 | 2029-12-10 | +1100 days |
| 2026-11-14 | Rosuvastatin, Laroprovstat | NCT06834932A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | Phase 2/3 | 2025-07-03 | 2027-02-22 | +599 days |
| 2026-11-14 | Nabiximols | NCT05503147Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan) | Phase 1 | 2023-08-01 | 2025-01-15 | +533 days |
| 2026-11-14 | Osimertinib | NCT05748093Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat | Phase 4 | 2026-06-01 | 2027-07-01 | +395 days |
| 2026-11-14 | Omega-3-acid ethyl esters (Lovaza) | NCT02178410VITAL Rhythm Study | Phase 3 | 2026-10 | 2027-10 | +365 days |
| 2026-11-14 | obefazimod | NCT07453784Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation | Phase 1 | 2026-09 | 2027-04 | +212 days |
| 2026-11-14 | aldesleukin | NCT06107894TIL Therapy for Patients With Advanced Solid Tumors | Phase 1 | 2025-09 | 2026-02-28 | +180 days |
| 2026-11-14 | upadacitinib | NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy | Phase 3 | 2028-03 | 2028-08 | +153 days |
| 2026-11-14 | Gemcitabine, Durvalumab | NCT07332351Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial | Phase 2 | 2027-01-01 | 2027-06-01 | +151 days |
| 2026-11-14 | Trastuzumab Emtansine, Inavolisib | NCT05894239A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | 2026-12-31 | 2027-05-03 | +123 days |
| 2026-11-14 | ADSTEM | NCT07377838Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis | Phase 3 | 2029-06 | 2029-09 | +92 days |
| 2026-11-14 | Suzetrigine | NCT07654296Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery | Phase 3 | 2026-12-31 | 2027-03-31 | +90 days |
| 2026-11-14 | AZD4954 | NCT07812077A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954 | Phase 1 | 2026-12-17 | 2027-03-17 | +90 days |
| 2026-11-14 | survodutide | NCT07407348A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body | Phase 1 | 2027-01-26 | 2027-04-09 | +73 days |
| 2026-11-14 | Omalizumab | NCT06618963Effect of Omalizumab in the Skin of Food Allergy Patients | Phase 4 | 2026-09 | 2026-11-03 | +63 days |
| 2026-11-14 | setmelanotide | NCT06772597A Study of Setmelanotide in Patients With Prader-Willi Syndrome | Phase 2 | 2026-10-31 | 2026-11-03 | +3 days |
| 2026-11-14 | Benralizumab | NCT03953300Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics | Phase 4 | 2026-10-19 | 2026-10-20 | +1 day |
| 2026-11-13 | Nivolumab | NCT04159818Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients | Phase 2 | 2022-12-15 | 2030-12-15 | +2922 days |
| 2026-11-13 | Axitinib | NCT06485908Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma | Phase 1/2 | 2026-04 | 2032-02 | +2132 days |
| 2026-11-13 | tenofovir alafenamide (Vemlidy) | NCT04939441Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) | Phase 4 | 2024-05-01 | 2027-12-31 | +1339 days |
| 2026-11-13 | Serplulimab | NCT05311189Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer | Phase 2 | 2023-12-31 | 2026-12-31 | +1096 days |
| 2026-11-13 | Mavacamten | NCT07807384Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Phase 4 | 2026-09 | 2029-09 | +1096 days |
| 2026-11-13 | LBL-034 | NCT06049290A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma | Phase 1/2 | 2026-10-20 | 2029-09-20 | +1066 days |
| 2026-11-13 | Methylprednisolone | NCT05139849VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial | Phase 3 | 2027-01-31 | 2029-01-31 | +731 days |
| 2026-11-13 | Atezolizumab | NCT05681039Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). | Phase 2 | 2026-11-01 | 2028-11-01 | +731 days |
| 2026-11-13 | Sargramostim, Ipilimumab, Pembrolizumab | NCT04739618Metastatic Solid Cancer Clinical Trial | Phase 2 | 2024-12 | 2026-11-10 | +709 days |
| 2026-11-13 | IRX4204 | NCT06723171Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis | Phase 2 | 2026-03 | 2027-12 | +640 days |
| 2026-11-13 | Rituximab | NCT06952413Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) | Phase 2 | 2026-09-30 | 2028-05-31 | +609 days |
| 2026-11-13 | AK146D1 | NCT06929663A Study of AK146D1 as Monotherapy and in Combination With AK104 or AK112, in the Treatment of Advanced Solid Tumors | Phase 1 | 2026-11-05 | 2028-06-30 | +603 days |
| 2026-11-13 | pemetrexed, Cadonilimab | NCT06762080Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis | Phase 1/2 | 2026-10-30 | 2027-12-30 | +426 days |
| 2026-11-13 | infliximab | NCT06758024PROactive and Early Infliximab Monitoring and oPTimization in Inflammatory Bowel Disease | Phase na | 2026-01 | 2027-03 | +424 days |
| 2026-11-13 | Anakinra | NCT03587701Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease | Phase 2 | 2026-12-31 | 2027-12-31 | +365 days |
| 2026-11-13 | Epcoritamab | NCT06510361A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy | Phase 2 | 2026-05-01 | 2027-05-01 | +365 days |
| 2026-11-13 | Decitabine/cedazuridine (Inqovi) | NCT05178693Lutathera and ASTX727 in Neuroendocrine Tumours | Phase 1 | 2026-06-30 | 2027-05-30 | +334 days |
| 2026-11-13 | Cetuximab | NCT06447987Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia | Phase 1 | 2026-12-05 | 2027-10-29 | +328 days |
| 2026-11-13 | LAE102 | NCT06493084Evaluate LAE102 in Healthy and Overweight/Obese Subjects | Phase 1 | 2026-09-30 | 2027-06-30 | +273 days |
| 2026-11-13 | Sotorasib | NCT06659341A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation | Phase 1 | 2027-04-26 | 2027-11-30 | +218 days |
| 2026-11-13 | Tislelizumab | NCT06420440Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model | Phase 2 | 2026-05-31 | 2026-12-31 | +214 days |
| 2026-11-13 | Niraparib | NCT05694715Combination Therapy in Cancers With Mutations in DNA Repair Genes | Phase 1 | 2028-01-31 | 2028-08-31 | +213 days |
| 2026-11-13 | Lithium salicylate/L-proline (AL001) | NCT07540338A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder | Phase 1/2 | 2026-12 | 2027-07 | +212 days |
| 2026-11-13 | Diroximel fumarate | NCT06913933Static vs. Dynamic Progressive Splinting for Persistent Wrist Stiffness After DRF | Phase na | 2026-04-17 | 2026-10-08 | +174 days |
| 2026-11-13 | Dexamethasone, Lenalidomide, Daratumumab, Carfilzomib | NCT03606577An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients | Phase 2 | 2022-02-08 | 2022-07-18 | +160 days |
| 2026-11-13 | XTR003 | NCT07443696PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy | Phase 2 | 2026-08 | 2026-12-31 | +152 days |
| 2026-11-13 | Emtricitabine (Emtriva), tenofovir alafenamide (Vemlidy), lamivudine (Epivir-HBV), Dolutegravir, VH4524184 | NCT07202546A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) | Phase 2 | 2027-06-11 | 2027-10-28 | +139 days |
| 2026-11-13 | Docetaxel, OSE2101 | NCT06472245Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | Phase 3 | 2027-12-15 | 2028-05-01 | +138 days |
| 2026-11-13 | BI 3000202 | NCT07774325A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood | Phase 1 | 2026-10-06 | 2027-02-21 | +138 days |
| 2026-11-13 | Esketamine | NCT07753772Dexmedetomidine-Esketamine Combination on Depression and Anxiety After Laparoscopic Ureteral Reconstruction | Phase 4 | 2029-07 | 2029-11 | +123 days |
| 2026-11-13 | Ifebemtinib | NCT06014528IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer | Phase 2 | 2026-12-24 | 2027-03-24 | +90 days |
| 2026-11-13 | Saruparib | NCT06713369AZD5305 hADME in Patients With Advanced Solid Malignancies | Phase 1 | 2026-10-02 | 2026-12-31 | +90 days |
| 2026-11-13 | Vadadustat | NCT06520826Vafseo Outcomes In-Center Experience | Phase 3 | 2026-06-30 | 2026-09-10 | +72 days |
| 2026-11-13 | Acoramidis | NCT07298044A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis | Phase 4 | 2027-07-15 | 2027-09-17 | +64 days |
| 2026-11-13 | Naloxone (Narcan) | NCT05027919Assessing a Clinically-meaningful Opioid Withdrawal Phenotype | Phase 2 | 2026-11-30 | 2027-01-30 | +61 days |
| 2026-11-13 | Gabapentin | NCT06565546CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs | Phase na | 2026-09-01 | 2026-10-31 | +60 days |
| 2026-11-13 | Everolimus | NCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | Phase 3 | 2026-12-30 | 2027-02-26 | +58 days |
| 2026-11-13 | tenofovir alafenamide (Vemlidy), Tenofovir disoproxil fumarate (Viread) | NCT02932150Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Phase 2 | 2026-09 | 2026-10-27 | +56 days |
| 2026-11-13 | MET-233i | NCT07022977A Study of MET233 in Individuals With Obesity or Overweight | Phase 1 | 2026-04-21 | 2026-05-28 | +37 days |
| 2026-11-13 | tocilizumab, Pembrolizumab | NCT07889232Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer | Phase 1/2 | 2029-04-30 | 2029-05-31 | +31 days |
| 2026-11-13 | Gemcitabine | NCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | Phase 2/3 | 2029-01-01 | 2029-01-31 | +30 days |
| 2026-11-13 | Odronextamab, Rituximab | NCT06091254A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | 2028-02-07 | 2028-02-29 | +22 days |
| 2026-11-13 | GSK4527363 | NCT06576271A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants | Phase 1 | 2028-01-11 | 2028-02-01 | +21 days |
| 2026-11-13 | Ruxolitinib (Opzelura) | NCT06959225Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | Phase 3 | 2026-10-09 | 2026-10-29 | +20 days |
| 2026-11-13 | Alimatravir | NCT07661108A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021) | Phase 1 | 2026-10-09 | 2026-10-28 | +19 days |
| 2026-11-13 | Sevabertinib, metformin | NCT07753252Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body | Phase 1 | 2026-10-06 | 2026-10-08 | +2 days |
| 2026-11-11 | pemetrexed, Cemiplimab | NCT07720167Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer | Phase 2 | 2029-11-01 | 2035-08-01 | +2099 days |
| 2026-11-11 | Methotrexate | NCT02205762LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis | Phase 2/3 | 2026-07 | 2031-11 | +1949 days |
| 2026-11-11 | Vemurafenib, Pertuzumab, Dabrafenib, Pemigatinib, Entrectinib, Cobimetinib, Abemaciclib, Regorafenib, Tepotinib, Alectinib, Trametinib, Atezolizumab | NCT05159245The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | Phase 2 | 2026-11-25 | 2031-11-25 | +1826 days |
| 2026-11-11 | Bevacizumab | NCT07005570Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer (SPARK) | Phase 2 | 2027-07-01 | 2031-12-31 | +1644 days |
| 2026-11-11 | Obinutuzumab, Gemcitabine | NCT06806033Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL | Phase 2 | 2027-01-31 | 2029-07-31 | +912 days |
| 2026-11-11 | Mepolizumab | NCT05923047Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study. | Phase 4 | 2024-09-01 | 2027-01-01 | +852 days |
| 2026-11-11 | Rituximab, Pirtobrutinib | NCT06263491Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients | Phase 2 | 2026-11-01 | 2028-11-01 | +731 days |
| 2026-11-11 | Brigatinib | NCT03707938Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | Phase 1 | 2026-01-28 | 2028-01-28 | +730 days |
| 2026-11-11 | Rilvegostomig | NCT04995523A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC | Phase 1/2 | 2026-08-28 | 2028-06-01 | +643 days |
| 2026-11-11 | lutikizumab, risankizumab | NCT06865105Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis | Phase 2 | 2027-12 | 2029-08 | +609 days |
| 2026-11-11 | Sintilimab | NCT06054906Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Gastric Cancer | Phase 2 | 2025-06-30 | 2026-12-30 | +548 days |
| 2026-11-11 | Colchicine (cardiovascular) | NCT06217120Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction | Phase 2 | 2025-10-01 | 2027-04 | +547 days |
| 2026-11-11 | Inclisiran | NCT06865885LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering | Phase 4 | 2026-12-30 | 2028-06-01 | +519 days |
| 2026-11-11 | Capecitabine, Gemcitabine | NCT06434493Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma | Phase na | 2028-06-01 | 2029-11-01 | +518 days |
| 2026-11-11 | Nab-paclitaxel, Gemcitabine | NCT03492671Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer | Phase 2 | 2026-09 | 2027-10 | +395 days |
| 2026-11-11 | metformin | NCT07001878Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis | Phase 4 | 2026-08-31 | 2027-09-30 | +395 days |
| 2026-11-11 | Mepolizumab | NCT06041386REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study | Phase 4 | 2025-01-31 | 2026-02-12 | +377 days |
| 2026-11-11 | Trastuzumab Deruxtecan, Olaparib | NCT06525298EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | Phase 1/2 | 2027-09 | 2028-09 | +366 days |
| 2026-11-11 | Cemiplimab | NCT05574101A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer | Phase 2 | 2026-10-06 | 2027-10-06 | +365 days |
| 2026-11-11 | Fianlimab, Cemiplimab | NCT06848088A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment | Phase 2 | 2029-10-10 | 2030-10-09 | +364 days |
| 2026-11-11 | Esketamine | NCT05450432Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | Phase 4 | 2026-06-01 | 2027-05-01 | +334 days |
| 2026-11-11 | Tislelizumab | NCT07557914Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes | Phase 2 | 2029-02 | 2029-12 | +303 days |
| 2026-11-11 | Fianlimab, Cemiplimab, Pembrolizumab | NCT05608291A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | Phase 3 | 2026-07-27 | 2027-01-15 | +172 days |
| 2026-11-11 | Bevacizumab | NCT06106308Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | Phase 2 | 2026-11 | 2027-04-16 | +166 days |
| 2026-11-11 | Gemcitabine | NCT06454383Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer | Phase 1 | 2026-11-13 | 2027-03-23 | +130 days |
| 2026-11-11 | Belumosudil | NCT07726914Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants | Phase 1 | 2026-09-28 | 2027-01-26 | +120 days |
| 2026-11-11 | Rosuvastatin, elecoglipron | NCT07534592A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants | Phase 1 | 2026-10-01 | 2027-01-25 | +116 days |
| 2026-11-11 | tocilizumab | NCT07254637Tocilizumab in Chronic Inflammatory CPPD Disease | Phase 2 | 2026-10 | 2026-11 | +31 days |
| 2026-11-11 | Bofanglutide | NCT07141030Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function | Phase 1 | 2025-10-09 | 2025-10-20 | +11 days |
| 2026-11-11 | zenagamtide, Semaglutide (Ozempic) | NCT07400107AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Phase 3 | 2028-12-12 | 2028-12-19 | +7 days |
| 2026-11-11 | Bofanglutide | NCT07355738Bioequivalence Study of GZR18 Injection Before and After CMC Change | Phase 1 | 2026-05-20 | 2026-05-22 | +2 days |
| 2026-11-10 | Pembrolizumab | NCT05394103Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Phase 1/2 | 2025-12-30 | 2029-03-31 | +1187 days |
| 2026-11-10 | IncobotulinumtoxinA (Xeomin) | NCT00909883Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles) | Phase 3 | 2011-09 | 2013-11-12 | +803 days |
| 2026-11-10 | Nivolumab | NCT05964101Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma | Phase 2 | 2025-08-01 | 2027-08-01 | +730 days |
| 2026-11-10 | Ambroxol | NCT06193421High-Dose Ambroxol in GBA1-Related Parkinson | Phase 1/2 | 2025-02-27 | 2026-03-30 | +396 days |
| 2026-11-10 | Quemliclustat | NCT05688215Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | Phase 1/2 | 2026-12-01 | 2027-12-31 | +395 days |
| 2026-11-10 | Tremelimumab, Durvalumab | NCT05701488SIRT With Tremelimumab and Durvalumab for Resectable HCC | Phase 1 | 2026-10-01 | 2027-10-01 | +365 days |
| 2026-11-10 | Cladribine (MAVENCLAD®), natalizumab | NCT04178005Cladribine Tablets After Treatment With Natalizumab (CLADRINA) | Phase 4 | 2026-08-30 | 2027-05-30 | +273 days |
| 2026-11-10 | Dexamethasone | NCT07607691Ultrasound-Guided PENG Block for Chronic Shoulder Pain | Phase na | 2026-10-01 | 2027-07-01 | +273 days |
| 2026-11-10 | Venetoclax, Ibrutinib, Lenalidomide, Obinutuzumab | NCT03223610Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | Phase 1/2 | 2026-12-01 | 2027-08-12 | +254 days |
| 2026-11-10 | Ruxolitinib (Jakafi) | NCT07278856Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas | Phase 1 | 2027-03-31 | 2027-12-10 | +254 days |
| 2026-11-10 | Idecabtagene vicleucel, Mezigdomide | NCT06048250Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma | Phase 1 | 2026-09-21 | 2027-02-09 | +141 days |
| 2026-11-10 | Rituximab, Acalabrutinib | NCT04002947Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | Phase 2 | 2027-05-31 | 2027-10-12 | +134 days |
| 2026-11-10 | Sacituzumab Tirumotecan, Pembrolizumab, Osimertinib | NCT05816252A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | Phase 2 | 2026-06-30 | 2026-08-31 | +62 days |
| 2026-11-10 | Olanzapine (Zyprexa) | NCT07581405GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer | Phase 2 | 2028-09 | 2028-11 | +61 days |
| 2026-11-10 | aldesleukin | NCT05194735Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | Phase 1/2 | 2023-08-14 | 2023-09-30 | +47 days |
| 2026-11-10 | Ziftomenib | NCT06930352Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy | Phase 2 | 2027-12-31 | 2028-01-31 | +31 days |
| 2026-11-10 | Sotagliflozin (Inpefa) | NCT06433050Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy | Phase 1 | 2027-04 | 2027-05 | +30 days |
| 2026-11-08 | Bosentan | NCT02377271ENDOTHELION Study Group: Effect of Bosentan in NAION Patients | Phase 3 | 2023-12 | 2027-02 | +1158 days |
| 2026-11-08 | Andecaliximab | NCT07024407A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton. | Phase 1/2 | 2025-12 | 2028-12 | +1096 days |
| 2026-11-08 | Tarlatamab, Durvalumab | NCT06211036Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab | Phase 3 | 2027-07-05 | 2030-04-02 | +1002 days |
| 2026-11-08 | Bevacizumab, Atezolizumab | NCT06823375SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis | Phase 2 | 2027-07-31 | 2029-03-31 | +609 days |
| 2026-11-08 | Lurbinectedin, Durvalumab | NCT07459634A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC | Phase 2 | 2028-01-31 | 2029-08-04 | +551 days |
| 2026-11-08 | Cannabidiol (Epidiolex) | NCT05015439Cannabidiol (CBD) in Adults With ASD | Phase 1 | 2026-12 | 2027-12 | +365 days |
| 2026-11-08 | Olanzapine (Zyprexa) | NCT06200181Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial | Phase 3 | 2026-11-01 | 2027-11-01 | +365 days |
| 2026-11-08 | Dexamethasone | NCT04150614BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron | Phase 4 | 2026-07 | 2027-03 | +243 days |
| 2026-11-08 | metformin | NCT06948825Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes | Phase 2 | 2026-11 | 2027-05 | +181 days |
| 2026-11-08 | Dexamethasone | NCT06304324Dexmedetomidine vs Dexamethasone in Popliteal Nerve Block | Phase 4 | 2025-03-31 | 2025-07-08 | +99 days |
| 2026-11-08 | Pertuzumab | NCT02320435A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial | Phase 3 | 2026-12-31 | 2027-03-28 | +87 days |
| 2026-11-08 | Bevacizumab | NCT07851025Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer | Phase 3 | 2030-06-18 | 2030-06-28 | +10 days |
| 2026-11-07 | Lumipodlin | NCT04964375A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor | Phase 1 | 2022-10-23 | 2027-07-30 | +1741 days |
| 2026-11-07 | infliximab-dyyb (Inflectra), Methotrexate, infliximab | NCT05072782Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL) | Phase 4 | 2023-06-30 | 2026-10-15 | +1203 days |
| 2026-11-07 | Ferric derisomaltose | NCT05971732The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF) | Phase 4 | 2024-08-01 | 2027-08-01 | +1095 days |
| 2026-11-07 | Ferric derisomaltose | NCT05991128The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life | Phase 4 | 2024-08-01 | 2027-08-01 | +1095 days |
| 2026-11-07 | Ruxolitinib (Jakafi) | NCT05622318De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis | Phase 2 | 2026-07 | 2028-07-08 | +738 days |
| 2026-11-07 | Ipilimumab, Nivolumab, Ciforadenant | NCT05501054Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. | Phase 1/2 | 2026-11-01 | 2028-11-01 | +731 days |
| 2026-11-07 | TNX-1500 | NCT07204080(TNX-1500) in Kidney Transplant Recipients | Phase 2 | 2029-09-01 | 2031-09-01 | +730 days |
| 2026-11-07 | Pembrolizumab | NCT04875585Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC | Phase 2 | 2023-12 | 2025-11-17 | +717 days |
| 2026-11-07 | tocilizumab, Abatacept | NCT03227419Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders | Phase 4 | 2024-09 | 2026-01-29 | +515 days |
| 2026-11-07 | R289 | NCT05308264Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Phase 1/2 | 2026-08 | 2027-12 | +487 days |
| 2026-11-07 | Dexamethasone | NCT06233604Dexamethasone vs. Dexmedetomidine for ESPB in Pain Management After Hip Arthroplasty | Phase 4 | 2025-03-30 | 2026-06-30 | +457 days |
| 2026-11-07 | YKST02 | NCT07695740Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma | Phase 2 | 2029-09 | 2030-12 | +456 days |
| 2026-11-07 | Anakinra | NCT04148430A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy | Phase 2 | 2026-10 | 2027-10 | +365 days |
| 2026-11-07 | Naltrexone | NCT06306157Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome | Phase 4 | 2026-08 | 2027-08 | +365 days |
| 2026-11-07 | Psilocybin (COMP360), Pimavanserin | NCT06592833Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder | Phase 2 | 2028-03-01 | 2029-03 | +365 days |
| 2026-11-07 | metformin | NCT06463743Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS) | Phase 2 | 2027-01-01 | 2027-12-01 | +334 days |
| 2026-11-07 | Ivonescimab | NCT06793332BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC | Phase 2 | 2026-01-31 | 2026-12-31 | +334 days |
| 2026-11-07 | Famitinib, Camrelizumab | NCT05999149A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) | Phase 3 | 2025-08-30 | 2026-05-30 | +273 days |
| 2026-11-07 | MRT-2359 | NCT05546268Study of Oral MRT-2359 in Selected Cancer Patients | Phase 1/2 | 2026-05 | 2026-12 | +214 days |
| 2026-11-07 | Dostarlimab | NCT05201547Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line | Phase 3 | 2026-04 | 2026-10-01 | +183 days |
| 2026-11-07 | Fampridine | NCT06136728Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis | Phase 3 | 2026-12 | 2027-05 | +151 days |
| 2026-11-07 | vedolizumab, ustekinumab | NCT06788340MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease | Phase 4 | 2027-08-30 | 2027-12-30 | +122 days |
| 2026-11-07 | Pembrolizumab | NCT07783581Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial | Phase 2 | 2030-04-01 | 2030-06-01 | +61 days |
| 2026-11-07 | Ziltivekimab | NCT06263244Specifying the Anti-inflammatory Effects of Ziltivekimab | Phase 3 | 2026-09-04 | 2026-10-30 | +56 days |
| 2026-11-07 | REGN20423 | NCT07527923First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis | Phase 1 | 2028-06-23 | 2028-08-14 | +52 days |
| 2026-11-07 | albuterol (Ventolin), Salbutamol HFA-152a | NCT06433921A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive | Phase 1 | 2027-02-26 | 2027-04-16 | +49 days |
| 2026-11-07 | pemetrexed, Osimertinib | NCT04769388Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib | Phase 2 | 2026-01-24 | 2026-01-26 | +2 days |
| 2026-11-07 | pemetrexed, Ramucirumab, Pembrolizumab | NCT04332367Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance | Phase 2 | 2026-09-30 | 2026-10-01 | +1 day |
| 2026-11-06 | baricitinib | NCT05056558Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19 | Phase 3 | 2022-04 | 2025-07-30 | +1216 days |
| 2026-11-06 | Azacitidine | NCT07433023tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy | Phase 2 | 2029-01-01 | 2030-08-31 | +607 days |
| 2026-11-06 | VH4524184 | NCT06310551First Time in Human Study of Long Acting VH4524184 Formulations | Phase 1 | 2028-01-21 | 2029-05-28 | +493 days |
| 2026-11-06 | Tamoxifen (Soltamox) | NCT07289035Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. | Phase 2 | 2026-04-01 | 2027-06-30 | +455 days |
| 2026-11-06 | Ramucirumab | NCT04660760Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | Phase 2 | 2024-07-31 | 2025-09-15 | +411 days |
| 2026-11-06 | metformin | NCT04194424A Multidisciplinary Weight Loss Program at AUB-MC | Phase na | 2026-09-15 | 2027-09-15 | +365 days |
| 2026-11-06 | Azacitidine (Onureg) | NCT06370000Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality | Phase 4 | 2027-01-31 | 2028-01-31 | +365 days |
| 2026-11-06 | Fianlimab, Cemiplimab | NCT07224022Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer | Phase 2 | 2028-12-31 | 2029-12-31 | +365 days |
| 2026-11-06 | Ferric derisomaltose | NCT06427343The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency | Phase 4 | 2026-09-30 | 2027-08-01 | +305 days |
| 2026-11-06 | Ribociclib, Trametinib, Capmatinib, Gefitinib | NCT03333343Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | Phase 1 | 2026-10-05 | 2027-07-12 | +280 days |
| 2026-11-06 | Enozertinib | NCT05315700Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Phase 1/2 | 2026-09 | 2027-06 | +273 days |
| 2026-11-06 | Empagliflozin | NCT05972564The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function | Phase 1/2 | 2026-09-30 | 2027-06-30 | +273 days |
| 2026-11-06 | IPS101A | NCT07371338Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients | Phase 1 | 2027-10-31 | 2028-06-30 | +243 days |
| 2026-11-06 | Dexamethasone | NCT07330999Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults | Phase na | 2027-01-01 | 2027-08-31 | +242 days |
| 2026-11-06 | Bevacizumab, Pazopanib | NCT01684397Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | Phase 1/2 | 2026-08-20 | 2027-02-20 | +184 days |
| 2026-11-06 | Ropeginterferon alfa-2b (Besremi) | NCT07468916Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia | Phase 2 | 2031-09-30 | 2032-01-30 | +122 days |
| 2026-11-06 | tovecimig | NCT07662031Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer | Phase 2 | 2030-08-31 | 2030-12-31 | +122 days |
| 2026-11-06 | Dexamethasone | NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | 2028-08-02 | 2028-11-30 | +120 days |
| 2026-11-06 | Etakafusp alfa, Pembrolizumab | NCT07300475Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients | Phase 1 | 2030-07-31 | 2030-09-30 | +61 days |
| 2026-11-06 | Aflibercept | NCT07798375A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration | Phase 2 | 2028-05 | 2028-07 | +61 days |
| 2026-11-06 | Aflibercept, Tabirafusp tedromer, Tarcocimab tedromer | NCT06556368A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | Phase 3 | 2026-08 | 2026-09-02 | +32 days |
| 2026-11-06 | Furosemide (subcutaneous, SQ Innovation) | NCT07018297Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure | Phase 3 | 2028-08-01 | 2028-09-01 | +31 days |
| 2026-11-06 | ABBV-295 | NCT07291232A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity | Phase 1 | 2027-03 | 2027-04 | +31 days |
| 2026-11-06 | Dexamethasone | NCT05688475A Rollover Study of CC-122 | Phase 1 | 2026-10-31 | 2026-11-30 | +30 days |
| 2026-11-06 | maridebart cafraglutide, Semaglutide (Ozempic) | NCT07866066Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Phase 3 | 2028-09-04 | 2028-09-06 | +2 days |
| 2026-11-05 | Gemcitabine, Cemiplimab, Nab-paclitaxel | NCT07433673Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC) | Phase 2 | 2028-01 | 2032-01 | +1461 days |
| 2026-11-05 | Hydroxychloroquine, Dexamethasone, apremilast, tocilizumab, Sarilumab, Anakinra, baricitinib | NCT02735707Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Phase 3 | 2026-02 | 2028-06 | +851 days |
| 2026-11-05 | bleximenib | NCT04811560A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) | Phase 1/2 | 2027-02-26 | 2028-12-29 | +672 days |
| 2026-11-05 | Docetaxel | NCT06042569Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial | Phase 2 | 2030-03-20 | 2031-09-20 | +549 days |
| 2026-11-05 | Rinatabart sesutecan (Rina-S), Bevacizumab, Pembrolizumab | NCT05579366Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | Phase 1/2 | 2027-07 | 2028-12 | +519 days |
| 2026-11-05 | Colchicine (cardiovascular) | NCT07654231REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial | Phase 2 | 2027-12-01 | 2029-05-01 | +517 days |
| 2026-11-05 | Pirfenidone (Esbriet) | NCT07654517Pirfenidone for Idiopathic Subglottic Stenosis: A Pilot Trial of Tolerability and Feasibility | Phase 1 | 2027-12-01 | 2029-03-31 | +486 days |
| 2026-11-05 | Epcoritamab, Rituximab, Lenalidomide | NCT05201248A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | Phase 1/2 | 2026-09 | 2027-10 | +395 days |
| 2026-11-05 | Sintilimab, Nab-paclitaxel | NCT05429463Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC(neoSCORE Ⅱ) | Phase 3 | 2025-11-11 | 2026-11-30 | +384 days |
| 2026-11-05 | Plerixafor | NCT02570542Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Phase 2 | 2026-10 | 2027-10 | +365 days |
| 2026-11-05 | Nab-paclitaxel, Gemcitabine | NCT02921022Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | Phase na | 2026-10 | 2027-10 | +365 days |
| 2026-11-05 | Neratinib | NCT02932280Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | Phase 1/2 | 2026-10 | 2027-10 | +365 days |
| 2026-11-05 | Pembrolizumab, Tarlatamab | NCT03319940Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | Phase 1 | 2026-12-31 | 2027-12-31 | +365 days |
| 2026-11-05 | Tamoxifen (Soltamox) | NCT03707340A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors | Phase 2 | 2026-10-14 | 2027-10-14 | +365 days |
| 2026-11-05 | N-acetylcysteine | NCT05081479A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma | Phase 1 | 2026-10-21 | 2027-10-21 | +365 days |
| 2026-11-05 | Nivolumab, Ipilimumab | NCT05663775Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) | Phase 2 | 2026-08 | 2027-08 | +365 days |
| 2026-11-05 | Temozolomide | NCT05664243A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | Phase 1/2 | 2025-12 | 2026-12 | +365 days |
| 2026-11-05 | Sotagliflozin (Inpefa) | NCT07211802CKM For Safe Use of SGLT2i in Type 1 Diabetes | Phase 3 | 2030-07-31 | 2031-07-31 | +365 days |
| 2026-11-05 | Atezolizumab | NCT06031441A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | 2027-03-03 | 2028-03-01 | +364 days |
| 2026-11-05 | metformin | NCT06452498Preeclampsia Intervention Netherlands | Phase 3 | 2028-04 | 2029-03-19 | +352 days |
| 2026-11-05 | Cabotegravir/rilpivirine (Cabenuva) | NCT05418868A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants | Phase 1 | 2027-06-08 | 2028-03-31 | +297 days |
| 2026-11-05 | Nab-paclitaxel, Gemcitabine, Tremelimumab, Durvalumab | NCT05451043Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | Phase 2 | 2026-10-01 | 2027-05-01 | +212 days |
| 2026-11-05 | Pembrolizumab | NCT05309421A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma | Phase 2 | 2025-09-30 | 2026-04-07 | +189 days |
| 2026-11-05 | Nab-paclitaxel | NCT06802757Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer | Phase 2 | 2026-06-30 | 2026-12-31 | +184 days |
| 2026-11-05 | Rituximab, Nivolumab | NCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | Phase 3 | 2026-12-31 | 2027-06-30 | +181 days |
| 2026-11-05 | Dexamethasone, Lenalidomide, Bortezomib | NCT05979363A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia | Phase 2 | 2026-07-01 | 2026-12-01 | +153 days |
| 2026-11-05 | Monalizumab, Oleclumab, Durvalumab | NCT05221840A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | Phase 3 | 2026-09-30 | 2027-01-08 | +100 days |
| 2026-11-05 | ALN-CIDEB | NCT06836609A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) | Phase 1/2 | 2027-05-15 | 2027-08-17 | +94 days |
| 2026-11-05 | Selinexor | NCT05099003A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Phase 1/2 | 2027-06-30 | 2027-09-30 | +92 days |
| 2026-11-05 | IMV102 | NCT07802756Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies | Phase 1 | 2027-09-10 | 2027-12-10 | +91 days |
| 2026-11-05 | Dapagliflozin | NCT07295223Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial) | Phase 3 | 2026-08 | 2026-10-30 | +90 days |
| 2026-11-05 | Omalizumab | NCT04045301Omalizumab to Accelerate a Symptom-driven Multi-food OIT | Phase 2 | 2025-12 | 2026-02-23 | +84 days |
Showing the newest 300 of 1,669 moves. Each drug page lists every registry date for its own studies.
Source: ClinicalTrials.gov, each study's record. A month-only date (YYYY-MM) is read as the first of the month, and a date that only gained or lost its day is not counted as a move. Every move we have recorded, not only the last 180 days, is a free CSV on the open data page.